UnknownPhase 1NCT00591058

Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma

Studying Oligodendroglioma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: TransMolecular
Principal Investigator: Burt Nabors, MD
University of Alabama at Birmingham
Intervention: TM-601(drug)
Enrollment: 36 target
Eligibility: 18 years · All sexes
Timeline: 2008 – 2010

Study locations (7)

University of Alabama, Birmingham, Alabama, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
Northwestern University, Chicago, Illinois, United States
Washington University, St Louis, Missouri, United States
Columbia University, New York, New York, United States
Wake Forest University, Winston-Salem, North Carolina, United States
University of Washington, Seattle, Washington, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00591058 on ClinicalTrials.gov

Other trials for Oligodendroglioma

Additional recruiting or active studies for the same condition.

See all trials for Oligodendroglioma →

← Back to all trials